Date: Wednesday, December 18, 2024
Time: 1:00pm – 2:00pm ET

Title:

Unmet Needs in Current Hemophilia Care: From Burdens to Breakthroughs

Description and Session Objectives:

To provide a clinical overview of the cost and treatment burden across all hemophilia types, the experience with current therapy, and unmet needs that may be addressed with novel therapies.

Target Audience:

All HTC Staff

Speakers:

Parin Chikani PharmD, MBA

Ryan Rodriguez PharmD, MS, BCPS

Parin Chikani, lives in the Chicagoland area and earned his Doctorate of Pharmacy degree from the University of Illinois at Chicago, College of Pharmacy and his MBA from Kellstadt Graduate School of Business. Before joining Novo Nordisk, Parin had been in the Pharmacy/Managed Care setting for over 15 years where he held many different roles and leadership positions within Pharmacy and Medical areas of the business. At Novo Nordisk, one of his roles and responsibilities is to ensure payors and clinicians are up-to-date on evidence based clinical and scientific information in the areas of Rare Diseases to help assist them with patient care.

Ryan Rodriguez is a Medical Liaison for rare blood disorders at Novo Nordisk covering the Midwest. His responsibilities include learning from and sharing medical information with clinicians who treat patients with hemophilia and other bleeding disorders, aligning with his passion for evidence-based patient care. Prior to joining Novo Nordisk, Ryan earned his PharmD degree from the University of Florida, and then served as Clinical Associate Professor at the University of Illinois Chicago College of Pharmacy, where he also earned his Master’s degree in epidemiology. Throughout his career, Ryan has been involved in medical communications, evidence generation and publication, and formulary management for various public and private entities.